This morning Champignon Brands Inc (CSE: SHRM) announced the appointment of Mr. Jay Kheita, ACPR, to its Special Advisory Committee, where he will help lead the integration of Champignon’s novel and natural treatment protocols into their existing consumer packaged goods portfolio. Khetia holds pharmacy licences in Canada, Australia and England. A graduate of the University of Brighton, where he achieved an honours degree in pharmacy studying the medicinal use of plants.
Khetia, co-founder of AltMed Capital, a leading Canadian psychedelic medicine clinic operator, IP aggregator and solutions provider, is currently a clinical advisor at the Leslie Dan faculty of pharmacy at the University of Toronto.
We are pleased to welcome Jay to Champignon’s Special Advisory Committee, where he will function as a cornerstone advisor throughout our pursuit to develop and deploy precision medicine focused formulations and delivery systems.
Gareth Birdsall, CEO of Champignon
Last week the company announced the acquisition of Tassili Life Sciences Corp; who is currently working in partnership with the University of Miami to develop effective psilocybin-based treatments for post traumatic stress disorder as well as mild traumatic brain injuries.
At the time of publishing, Champignon’s share price has risen 5.0% to 52c.
FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
A Look at C21 Investments Q2 Financials
Last night C21 Investments (CSE: CXXI) released their second quarter earnings. They showed a 28.6%...